Bowmed Ibisqus joins the ACS Dobfar Group

Following yesterday’s announcement that IBI – Istituto Biochimico Italiano Giovanni Lorenzini and its subsidiaries have joined the ACS Dobfar Group, Bowmed Ibisqus is pleased to begin an exciting new chapter as part of the wider ACS Dobfar organisation.

For our customers, suppliers and partners, our focus remains unchanged – Bowmed will continue to support the UK healthcare market with the same commitment to product quality, reliable supply and responsive service that has been at the heart of our business for more than 20 years, and we look forward to the next phase of our evolution.

As part of the ACS Dobfar Group, Bowmed now sits within an established international pharmaceutical organisation with extensive expertise in the development, manufacture and supply of medicines, including antibiotics and sterile hospital products. We look forward to working alongside our new colleagues across the ACS Dobfar Group as we continue to build on the expertise, experience and strong relationships that have helped shape our success.

The official Group press release can be found below.

Official Press Release